HTG Molecular Diagnostics, Inc. ("HTG") is a provider of instruments, reagents, and services for molecular profiling applications. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTG’s proprietary nuclease protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power of HTG EdgeSeq chemistry and automation with next-generation sequencing (NGS) technology. In 2016, the VERI/O Laboratory Services were introduced to support biopharma clients in research and companion diagnostic development using retrospective samples. Most recently, in 2017, HTG introduced its new DNA mutations chemistry available exclusively in the VERI/O Laboratory Services.
I positively impact customer satisfaction daily.
I understand and embrace my contribution in achieving the company results.
I foster a trustful environment where open and honest feedback is valued and encouraged.
I make data-driven decisions and clearly communicate how and why each decision impacts the results.
I make commitments and take accountability for results.
I develop and continuously improve processes to consistently meet requirements.
I recognize individual contributions and celebrate organizational successes.
HTG's mission is to empower precision medicine at the local level
John L. Lubniewski
President, Chief Executive Officer and Member of the Board of Directors
Shaun D. McMeans
Senior Vice President of Finance, Administration, and Chief Financial Officer
Byron T. Lawson
Senior Vice President and Chief Commercial Officer
Marian Navratil, PhD.
Senior Vice President of Research & Development
Laura L. Godlewski
Vice President of Finance and Principal Accounting Officer
Ann F. Hanham, Ph.D.
Chair of the Board of Directors
Harry A. George
Michelle R. Griffin
Donnie (Don) M. Hardison
James (Jim) T. LaFrance
John L. Lubniewski
Lee R. McCracken
Assistant Professor of Oncological Sciences
Precision Immunology Institute/Tisch Cancer Institute
Dr. Horowitz’s work has contributed to developing an understanding of adaptive natural killer (NK) cells and their roles in microbial infections, cancers and following vaccination and transplantation. He pioneered the first studies of human NK cells by mass cytometry (CyTOFTM) and demonstrated an enormous breadth of phenotypic diversity and functions associated with specific human leukocyte antigen (HLA) class I and killer cell Ig-like receptors (KIR) backgrounds. This research has led to the identification and characterization of numerous NK cell subset populations with unique activity and immunotherapeutic potential. This work and related future research will address his long-term career goal of understanding how immunogenetic variation governs the education of NK cells and their ability to function within dynamic environments.
Dr. Horowtiz first obtained expertise in immunology and infectious diseases with David Ho (Rockefeller University) and with Eleanor Riley (London School of Hygiene and Tropical Medicine). He then pursued a post-doctoral expertise in evolutionary and population immunogenetics, structural biology, and epidemiology with Peter Parham (Stanford University). He also cultivated long-standing collaborations with leading scientists in the field of NK cell and innate immunology and HLA genetics (Daniel Davis, University of Manchester; Jeffrey Miller, University of Minnesota; Ashley Moffett, University of Cambridge; Francesco Colluci, University of Cambridge; Karl-Johan Malmberg, Karolinska Institute, and University of Oslo; Mary Carrington, National Cancer Institute; Bruce Walker, Ragon Institute of MGH, MIT and Harvard; Timothy Chan, Memorial Sloan Kettering; Nina Bhardwaj and Miriam Merad, Mount Sinai).
His work has contributed to developing an understanding of adaptive NK cells and their roles in microbial infections and following vaccination and hematopoietic cell transplantation (HCT). This research has led to the identification and characterization of numerous NK cell subset populations with unique activity and antiviral (and anti-tumor) potential.
Resident Research Director
Professor of Surgery
Professor in Pathology
David H. Harpole, Jr. is a Professor of Surgery in the Division of Thoracic Surgery at the Duke University Medical Center (DUMC) in Durham, North Carolina, where he serves as Director of the Surgical Residency Research Fellowship, as well as the Thoracic Oncology Research Laboratory and Biorepository. Dr. Harpole received his medical degree from the University of Virginia in Charlottesville, Virginia in 1980 and completed his General and Thoracic Surgery Residencies in 1993 under Dr. David Sabiston at DUMC where he also was the Posthelwaite Thoracic Research fellow from 1986-1988. After completion, he joined the faculty of the Division of Thoracic Surgery at the Brigham and Women’s Hospital and the Dana Farber Cancer Institute of the Harvard Medical School under the leadership of Dr. David Sugarbaker from 1993-1996 when he returned to DUMC to establish the General Thoracic Surgery program with Dr. Thomas D’Amico.
Over the past 20+ years, Dr. Harpole has served as Vice-chairman for Faculty Affairs, Vice-chief of The Division of Surgical Sciences and Vice Chairman for Research in the Department of Surgery. He also served as the Surgical coordinator for DUMC, Cancer and Leukemia Group B, Chairman of the Society of Thoracic Surgeons: General Thoracic Surgery Database Committee, Chairman of the Thoracic Surgery Sub-committee, CALGB and Vice-chairman, American College of Surgeons Oncology Group. He also is the Co-chair of the Thoracic Tumor Committee of the National Cancer Database and recently retired as a Director of the American Board of Thoracic Surgery.
He has contributed numerous articles (> 200) and abstracts to the medical literature. His work on mesothelioma, non-small cell lung cancer, and esophageal carcinoma has appeared in Journal of Thoracic & Cardiovascular Surgery, Clinical Cancer Research, Journal of Clinical Oncology, Journal of Thoracic Oncology, Cancer, and Lung Cancer. His work has also been presented at the national meetings of ASCO, AACR, STS, and the IASLC. He has directed an active translational thoracic oncology research laboratory for 25 years that has had continuous NIH, VA, or DOD peer reviewed grant support and has served on NCI and VA grant review study sections for more than 15 years. Most recently over the last 8 years, he has led the NCI-CTEP Thoracic Malignancies Steering Committee that oversees all large clinical trials in lung cancer and mesothelioma. This committee is made up of oncologists and scientists from the U.S. and Canada who approves and oversees all lung cancer, mesothelioma, and thymoma clinical trials in North America. He has directed the Duke Lung Cancer Research Laboratory for 20-years It focuses on the genomics of lung cancer and mesothelioma: “Why cancers form, grow and spread, and how to develop new drugs to treat this?” He has been a member of the IASLC Board of Directors since 2015.
Department of Translational Molecular Pathology,
Division of Pathology/Lab,
Professor of Medicine,
Department of Thoracic/Head and Neck Medical Oncology,
Division of Cancer Medicine
Ignacio I. Wistuba, M.D., is Professor and Chair of the Department of Translational Molecular Pathology, with a joint appointment in Thoracic/Head and Neck Medical Oncology, and one of the co-directors of the Khalifa Institute for Personalized Cancer Therapy (IPCT) at M.D. Anderson Cancer Center in Houston, Texas. He is also Director of the Thoracic Molecular Pathology Laboratory, co-leader of the institutional Tissue Bank and Pathology Resources, and director of the ECOG-ACRIN Central Biorepository and Pathology Facility.
Dr. Wistuba is a surgical and molecular pathology specialist with a strong record of scientific achievement in lung cancer with over 500 peer-reviewed papers and several book chapters to his credit. His research interests include the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer, and the identification of novel molecular targets and validation of biomarkers for targeted- and immune-therapies.
At MD Anderson Cancer Center, Dr. Wistuba oversees biomarker studies for lung cancer therapeutic and other solid tumors clinical trials, and he is co-leader of the Moon-Shot APOLLO platform. He currently serves as the pathologist of the Lung Cancer Committee for the Southwestern Oncology Group (SWOG), the Lung Cancer Mutation Consortium (LCMC), and chair of the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC). Dr. Wistuba is the contact Principle Investigator of three NIH/NCI U24 grants, including the MD Anderson Center for Immune Monitoring and Analysis of Cancer (CIMAC). He serves as senior editor of Cancer Prevention Research (AACR) and Annals of Oncology (ESMO).
Chief, Genitourinary Malignancies Branch, CCR
Head, Clinical Immunotherapy Section, GMB, CCR
Director, Medical Oncology Service, CCR, NCI
As Chief of the Genitourinary Malignancies Branch and Head of the Clinical Immunotherapy Section, Dr. James Gulley oversees one of the busiest clinical programs in the Center for Cancer Research (CCR). CCR enrolls 250 – 300 patients a year for therapeutic clinical trials, largely studies of immunotherapy. His group has focused on T cell-poor tumors such as prostate cancer and the development of strategies to optimize immunological approaches for effective therapy. Their overriding strategy has been to concentrate on opportunities to focus the immune response through vaccines or adoptive cellular therapy and then facilitate effector function of those activated immune cells within the tumor microenvironment through approaches including immune checkpoint modulation.
Dr. Gulley has been involved in the clinical development of Prostvac from the first-in-human studies at the CCR through a completed 1,297-subject phase III clinical trial that he led. While there was no improvement in overall survival seen with vaccine alone, it was discovered that vaccine alone can induce a systemic immune response and lead to increased immune cell infiltrate within the tumor. Ongoing work is looking at combining vaccine with strategies to facilitate tumor specific T-cell function in the typically immune hostile tumor microenvironment.
He was selected to lead an international first-in-human study of avelumab (n>1,700), an immune checkpoint modulator initiated at the CCR, that has been rapidly taken into phase III testing based on their work with an approval in early 2017 for Merkel cell carcinoma and bladder cancer, and another international study of M7824, a novel bifunctional protein targeting PDL1 and TGF-β (n>450) and is most enthusiastic about their ongoing and planned multiple CCR-originated studies of immune checkpoint combination approaches (e.g., vaccine and immune checkpoint inhibitor).
Professor of Medical Oncology, Department of Medical Oncology,
Department of Translational Research and Innovation
Pierre Saintigny, M.D., Ph.D., is a medical oncologist and physician-scientist trained at the University of Paris School of Medicine. He completed his training as a postdoctoral fellow and clinical fellow in the Department of Thoracic / Head and Neck Medical Oncology at the University of Texas M.D. Anderson Cancer Center, Houston, Texas where he got his first faculty position as an Assistant Professor. Since 2013, he is serving the Organization of European Cancer Institutes (OECI)-accredited comprehensive Cancer Centre Léon Bérard in Lyon, France. He is affiliated to the Department of Medical Oncology, the Department of Translational Research, and Innovation and the Cancer Research Center of Lyon (CRCL).
Dr. Saintigny is focusing his research on the lung and head and neck field and involved in the development of precision medicine through his active participation to the Worldwide Innovative Network (WIN) Association and to the French large-scale sequencing program Plan France Médecine Génomique 2025.
Page last updated August 09, 2021